This company has been marked as potentially delisted and may not be actively trading. TenX Keane Acquisition (TENK) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsOwnershipTrendsBuy This Stock TENK vs. CARM, CMMB, COCP, NXTC, MEIP, SLGL, BCTX, NRSN, EGRX, and SYBXShould you be buying TenX Keane Acquisition stock or one of its competitors? The main competitors of TenX Keane Acquisition include Carisma Therapeutics (CARM), Chemomab Therapeutics (CMMB), Cocrystal Pharma (COCP), NextCure (NXTC), MEI Pharma (MEIP), Sol-Gel Technologies (SLGL), BriaCell Therapeutics (BCTX), NeuroSense Therapeutics (NRSN), Eagle Pharmaceuticals (EGRX), and Synlogic (SYBX). These companies are all part of the "pharmaceutical products" industry. TenX Keane Acquisition vs. Carisma Therapeutics Chemomab Therapeutics Cocrystal Pharma NextCure MEI Pharma Sol-Gel Technologies BriaCell Therapeutics NeuroSense Therapeutics Eagle Pharmaceuticals Synlogic Carisma Therapeutics (NASDAQ:CARM) and TenX Keane Acquisition (NASDAQ:TENK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk. Do institutionals and insiders hold more shares of CARM or TENK? 44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 70.5% of TenX Keane Acquisition shares are held by institutional investors. 12.6% of Carisma Therapeutics shares are held by insiders. Comparatively, 22.9% of TenX Keane Acquisition shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in CARM or TENK? Carisma Therapeutics received 18 more outperform votes than TenX Keane Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformCarisma TherapeuticsOutperform Votes1878.26% Underperform Votes521.74% TenX Keane AcquisitionN/AN/A Which has higher earnings and valuation, CARM or TENK? TenX Keane Acquisition has lower revenue, but higher earnings than Carisma Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$19.63M0.41-$86.88M-$1.56-0.12TenX Keane AcquisitionN/AN/AN/AN/AN/A Is CARM or TENK more profitable? TenX Keane Acquisition has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -314.78%. TenX Keane Acquisition's return on equity of 0.00% beat Carisma Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-314.78% -957.20% -96.39% TenX Keane Acquisition N/A N/A N/A Does the media refer more to CARM or TENK? In the previous week, Carisma Therapeutics had 8 more articles in the media than TenX Keane Acquisition. MarketBeat recorded 8 mentions for Carisma Therapeutics and 0 mentions for TenX Keane Acquisition. TenX Keane Acquisition's average media sentiment score of 0.00 beat Carisma Therapeutics' score of -0.15 indicating that TenX Keane Acquisition is being referred to more favorably in the news media. Company Overall Sentiment Carisma Therapeutics Neutral TenX Keane Acquisition Neutral Do analysts recommend CARM or TENK? Carisma Therapeutics currently has a consensus target price of $2.74, indicating a potential upside of 1,330.06%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Carisma Therapeutics is more favorable than TenX Keane Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.43TenX Keane Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryCarisma Therapeutics beats TenX Keane Acquisition on 7 of the 13 factors compared between the two stocks. Remove Ads Get TenX Keane Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for TENK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TENK vs. The Competition Export to ExcelMetricTenX Keane AcquisitionHolding Offices Industry SectorNASDAQ ExchangeMarket Cap$4.59M$435.52M$2.35B$7.12BDividend YieldN/A7.67%13.73%4.10%P/E RatioN/A2.1211.0917.50Price / SalesN/A48.143,539,395.0788.77Price / CashN/A69.0172.7334.64Price / BookN/A3.263.143.79Net IncomeN/A$35.22M-$293.66M$247.56M TenX Keane Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TENKTenX Keane AcquisitionN/A$0.69-2.4%N/A-93.8%$4.59MN/A0.00N/AGap DownHigh Trading VolumeCARMCarisma Therapeutics2.8033 of 5 stars$0.40+1.6%$4.94+1,134.7%-89.5%$16.44M$20.27M-0.2620Upcoming EarningsAnalyst ForecastNews CoverageCMMBChemomab Therapeutics3.3323 of 5 stars$1.14-8.1%$9.00+689.5%+31.3%$16.37MN/A-1.1420Gap DownCOCPCocrystal Pharma3.0024 of 5 stars$1.48-6.3%$7.00+373.0%-11.0%$16.08MN/A-0.8010Analyst RevisionNews CoverageNXTCNextCure3.9399 of 5 stars$0.57-6.6%$3.50+515.1%-82.1%$15.94MN/A-0.2790News CoverageHigh Trading VolumeMEIPMEI Pharma3.701 of 5 stars$2.35flat$7.00+197.9%-46.7%$15.66M$65.30M-0.41100Gap DownSLGLSol-Gel Technologies2.5122 of 5 stars$0.56-2.0%$5.00+794.5%-52.7%$15.57M$11.71M-1.6450BCTXBriaCell Therapeutics1.1294 of 5 stars$4.09-8.3%$32.00+682.4%-90.3%$15.17MN/A-0.318News CoverageNRSNNeuroSense Therapeutics0.3129 of 5 stars$1.10+1.9%N/A-41.8%$15.03MN/A-1.7210News CoverageGap DownEGRXEagle PharmaceuticalsN/A$1.15-20.7%N/A-63.2%$14.94M$257.55M0.00100Analyst ForecastGap DownSYBXSynlogicN/A$1.28-3.4%N/A-39.3%$14.91M$8,000.00-0.3180Gap Down Remove Ads Related Companies and Tools Related Companies CARM Alternatives CMMB Alternatives COCP Alternatives NXTC Alternatives MEIP Alternatives SLGL Alternatives BCTX Alternatives NRSN Alternatives EGRX Alternatives SYBX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TENK) was last updated on 4/6/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TenX Keane Acquisition Please log in to your account or sign up in order to add this asset to your watchlist. Share TenX Keane Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
